Guidelines: Difference between revisions
Urology4all (talk | contribs) |
Urology4all (talk | contribs) |
||
| Line 77: | Line 77: | ||
==== Contribute ==== | ==== Contribute ==== | ||
* [https://www.auanet.org/guidelines-and-quality/guidelines/salvage-therapy-for-prostate-cancer Salvage Therapy for Prostate | * Overactive Bladder (2024) | ||
*Incontinence after Prostate Therapy (2024) | |||
*Non-muscle Invasive Bladder Cancer (2024) | |||
*[https://www.auanet.org/guidelines-and-quality/guidelines/salvage-therapy-for-prostate-cancer Salvage Therapy for Prostate Cancer (2024)] | |||
*Diagnosis and Treatment of Early Stage Testicular Cancer (2024) | *Diagnosis and Treatment of Early Stage Testicular Cancer (2024) | ||
*Management of LUTS attributed to BPH (2023) | |||
*Interstitial Cystitis/Bladder Pain Syndrome (2022) | *Interstitial Cystitis/Bladder Pain Syndrome (2022) | ||
*[[AUA: Neurogenic LUTD (2021)|Neurogenic LUTD (2021)]] | *[[AUA: Neurogenic LUTD (2021)|Neurogenic LUTD (2021)]] | ||